Mother’s Pregnancy Trimester Does Not Affect the Differences of IgG SARS-COV-2 Antibody Levels in Pregnant Women after mRNA and Inactivated Coronavirus Disease 2019 Vaccination
DOI:
https://doi.org/10.3889/oamjms.2023.11237Keywords:
COVID-19, IgG SARS-CoV-2, inactivated vaccine, mRNA vaccine, pregnancy trimesterAbstract
BACKGROUND: Since pregnancy increases the risk of coronavirus disease 2019 (COVID-19) and its morbidity in pregnant women, it is necessary and recommended to prevent COVID-19 in pregnant women by vaccination such as by messenger RNA (mRNA) and inactivated vaccines. SARS-CoV-2 antibodies produced from vaccination have different results according to the type of vaccine given. The previous studies showed that IgG SARS-CoV-2 antibody levels were influenced by various factors such as gestational weeks at the time when vaccines were given. Moreover, there have been no previous studies on the effect of gestational age on quantitative IgG levels after the second dose of the vaccine especially in Indonesia during this pandemic due to some restrictions on daily activities.
AIM: The aim of this study is to see the effect of giving the COVID-19 vaccine based on maternal gestational age (in trimester units) on maternal immunity (IgG SARS-CoV-2) in Dr. Hasan Sadikin General Hospital Bandung, Bandung Kiwari Hospital and Dr. Slamet Hospital, Garut.
METHODS: This was a retrospective and cohort study by taking secondary data using consecutive sampling from the previous tests on the levels of SARS-CoV-2 IgG antibodies after two doses of inactivated vaccine and mRNA. Healthy pregnant women 14–34 weeks at the Department of Obstetrics and Gynecology, Dr. Hasan Sadikin (RSHS) Bandung, Bandung Kiwari Hospital, and Dr. Slamet Hospital for the period October 2021 to January 2022 were the target population of this study. Based on inclusion and exclusion criteria, 103 samples met the criteria. Examination of Maternal SARS-CoV-2 IgG Antibody Levels procedures was carried out using Chemiluminescent Microparticle Immunoassay. Statistical analysis was done using IBM SPSS 28.00 and p < 0.05 was considered statistically significant.
RESULTS: There was no significant difference (p = 0.236, p > 0.05) between the mean maternal age in the mRNA and inactivated vaccine groups. The mRNA and inactivated vaccine groups also had no significant difference in the gestational age category (0.70). There was a significant difference (p = 0.0001) between the levels of SARS-CoV-2 IgG antibodies after the vaccine in the mRNA and inactivated vaccine groups. There was no significant difference in the levels of SARS-CoV-2 IgG antibodies in the gestational age group after the mRNA vaccine (p = 0.426) and after the inactivated vaccine (p = 0.293). There was a significant difference (p < 0.05) in the subgroup analysis in each gestational age group (second trimester and third trimester) between SARS-CoV-2 IgG antibody levels after the mRNA vaccine compared to inactivated vaccine.
DISCUSSIONS: The mRNA vaccine is based on the principle that mRNA is an intermediate messenger to be translated to an antigen after delivery to the host cell via various routes. However, inactivated vaccines contain viruses whose genetic material has been destroyed by heat, chemicals, or radiation, so they cannot infect cells and replicate but can still trigger an immune response. The administration of the vaccine in the second and third trimesters of pregnancy has the same results in increasing levels of SARS-CoV-2 IgG antibodies after mRNA and inactivated vaccination in this study.
CONCLUSIONS: mRNA vaccination in pregnant women is better than inactivated vaccines based on the levels of IgG SARS-CoV-2 antibodies after vaccination. The maternal trimester of pregnancy was not a factor influencing the levels of SARS-CoV-2 IgG antibodies after either mRNA or inactivated COVID-19 vaccinations in this study.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kachikis A, Englund JA, Singleton M, Covelli I, Drake AL, Eckert LO. Short-term reactions among pregnant and lactating individuals in the first wave of the COVID-19 vaccine rollout. JAMA Network Open. 2021;4(8):e2121310. https://doi.org/10.1001/jamanetworkopen.2021.21310 PMid:34402893 DOI: https://doi.org/10.1001/jamanetworkopen.2021.21310
WHO. Weekly epidemiological update on COVID-19. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/ item/weekly-epidemiological-update-on-covid-19 [Last accessed on 2022 Feb 10].
Perhimpunan Obstetri dan Ginekologi Indonesia (POGI). Rekomendasi Penanganan Infeksi Virus Corona (Covid-19) Pada Maternal. Jakarta: Maret; 2020. p. 1-28.
Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Available from: https://covid.cdc.gov/ covid-data-tracker [Last accessed on 2022 Feb 11].
Terentes-Printzios D, Gardikioti V, Solomou E, Emmanouil E, Gourgouli I, Xydis P, et al. The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness. Hypertens Res. 2022;45(5):846-55. https://doi.org/10.1038/s41440-022-00876-6 PMid:35273351 DOI: https://doi.org/10.1038/s41440-022-00876-6
Garg I, Shekhar R, Sheikh AB, Pal S. COVID-19 vaccine in pregnant and lactating women: A review of existing evidence and practice guidelines. Infect Dis Rep. 2021;13(3):685-99. https://doi.org/10.3390/idr13030064 PMid:34449637 DOI: https://doi.org/10.3390/idr13030064
Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273-82. DOI: https://doi.org/10.1056/NEJMoa2104983
WHO. Questions and Answers: COVID-19 Vaccines and Pregnancy; 2022. Available from: https://media.tghn.org/ medialibrary/2021/09/COVAX_FAQ_on_TTS_15Sep2021.pdf [Last accessed on 2022 Feb 11].
POGI. Rekomendasi Penanganan Infeksi Virus Corona (Covid- 19). Jakarta: Maret; 2020. p. 1-28.
WHO. Update on WHO Interim Recommendations on COVID-19 Vaccination of Pregnant and Lactating Women; 2021. Available from: http://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization [Last accessed on 2022 Feb 11].
Wilder-Smith A, Mulholland K. Effectiveness of an inactivated SARS-CoV-2 vaccine. N Engl J Med. 2021;385(10):946-8. https://doi.org/10.1056/NEJMe2111165 PMid:34469651 DOI: https://doi.org/10.1056/NEJMe2111165
Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475-84. https://doi.org/10.1038/s41577-021-00578-z PMid:34211186 DOI: https://doi.org/10.1038/s41577-021-00578-z
WHO. Interim Recommendations for the Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac Interim Guidance; 2021. Available from: https://www.who.int/groups/ strategic-advisory-group-of-experts-on-immunization/covid-19- materials [Last accessed on 2022 Feb 11].
WHO. Interim Recommendations for Use of the Moderna mRNA-1273 Vaccine against COVID-19; 2021. Available from: https://www.who.int/groups/strategic [Last accessed on 2022 Feb 11].
Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533-5. https://doi.org/10.1001/jama.2021.15125 PMid:34459863 DOI: https://doi.org/10.1001/jama.2021.15125
Bayart JL, Morimont L, Closset M, Wieërs G, Roy T, Gerin V, et al. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2; 2021. DOI: https://doi.org/10.20944/preprints202106.0237.v1
Kugelman N, Nahshon C, Shaked-Mishan P, Cohen N, Sher ML, Gruber M, et al. Maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at delivery after receipt of the BNT162b2 messenger RNA COVID-19 vaccine during the second trimester of pregnancy. JAMA Pediatr. 2022;176(3):290-5. https://doi.org/10.1001/jamapediatrics.2021.5683 PMid:34932066 DOI: https://doi.org/10.1001/jamapediatrics.2021.5683
MacIntyre CR, Costantino V, Trent M. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine. 2022;40(17):2506- 13. https://doi.org/10.1016/j.vaccine.2021.04.042 PMid:33958223 DOI: https://doi.org/10.1016/j.vaccine.2021.04.042
Gay L, Diehl P. Research Methods for Business and Management. New York: Macmillan; 1992.
Halim M. COVID-19 vaccination efficacy and safety literature review. J Immunol Allergy. 2021;3(1):1-10. DOI: https://doi.org/10.37191/Mapsci-2582-4333-3(1)-058
Park JW, Lagniton PN, Liu Y, Xu RH. mRNA vaccines for COVID-19: What, why and how. Int J Biol Sci. 2021;17(6):1446. https://doi.org/10.7150/ijbs.59233 PMid:33907508 DOI: https://doi.org/10.7150/ijbs.59233
Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508-17. https://doi.org/10.1016/j.csbj.2021.04.061 PMid:33936564 DOI: https://doi.org/10.1016/j.csbj.2021.04.061
Mathew S, Faheem M, Hussain NA, Benslimane FM, Al Thani AA, Zaraket H, et al. Platforms exploited for SARS-CoV-2 vaccine development. Vaccines. 2020;9(1):11. https://doi.org/10.3390/vaccines9010011 PMid:33375677 DOI: https://doi.org/10.3390/vaccines9010011
Yang YJ, Murphy EA, Singh S, Sukhu AC, Wolfe I, Adurty S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol. 2022;139(3):373-80. https://doi.org/10.1097/AOG.0000000000004693 PMid:34963127 DOI: https://doi.org/10.1097/AOG.0000000000004693
Anderson E, Brigden A, Davies A, Shepherd E, Ingram J. Maternal vaccines during the Covid-19 pandemic: A qualitative interview study with UK pregnant women. Midwifery. 2021;100:103062. https://doi.org/10.1016/j.midw.2021.103062 PMid:34198208 DOI: https://doi.org/10.1016/j.midw.2021.103062
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Anita Deborah Anwar, Putri Nadhira Adinda Adriansyah, Ivan Christian Channel, Annisa Dewi Nugrahani, Febriani Febriani, Asep Surachman, Dhanny Primantara Johari Santoso, Akhmad Yogi Pramatirta, Budi Handono (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
